Immunohistochemical evaluation of PCNA, p53, HSP60, HSP10 and MUC-2 presence and expression in prostate carcinogenesis.
Immunohistochemical evaluation of PCNA, p53, HSP60, HSP10 and MUC-2 presence and expression in prostate carcinogenesis.
复制标题
DOI：
--
复制
发表时间：
2003-03
影响因子：
2
通讯作者：
F. Cappello;F. Rappa;S. David;R. Anzalone;G. Zummo
中科院分区：
文献类型：
--
作者：
F. Cappello;F. Rappa;S. David;R. Anzalone;G. Zummo
背景研究不同生物标志物在前列腺非肿瘤性、肿瘤前和肿瘤性病变中的表达，有助于更好地了解它们在致癌过程中的作用，并找到新的诊断和预后工具。材料与方法在本研究中，我们通过免疫组织化学方法评价了PCNA、p53、HSP 60、HSP 10和MUC-2在一系列结节性增生、低度和高度前列腺上皮内病变和腺癌中的存在和表达。结果：1）PCNA表达与前列腺癌的进展程度有关; 2）p53突变可能是前列腺癌发生的晚期事件。此外，我们报告说：1）HPS 60和HPS 10在前列腺癌发生早期过表达; 2）MUC-2在肿瘤和非肿瘤前列腺组织中均不存在。结论我们建议通过分子和遗传学研究进一步研究HSP 60和HSP 10在前列腺以及其他器官癌变过程中的作用。
BACKGROUND The study of the expression of different biological markers in non-neoplastic, pre-neoplastic and neoplastic lesions of prostate could help to better understand their role in carcinogenesis and to find new diagnostic and prognostic tools. MATERIALS AND METHODS In the present work we evaluated, by immunohistochemistry, the presence and the expression of PCNA, p53, HSP60, HSP10 and MUC-2 in a series of nodular hyperplasia, low- and high-grade prostatic intraepithelial lesions and adenocarcinomas. RESULTS Our data confirmed that: 1) PCNA expression could be related to the grade of progression of cancer; and that 2) p53 mutation could be a late event in prostate carcinogenesis. Moreover, we reported that: 1) HPS60 and HPS10 were overexpressed early in prostate carcinogenesis; and that 2) MUC-2 is absent in both tumoral and non-tumoral prostatic tissue. CONCLUSION We suggest the further examination, by molecular and genetic studies, of the role of HSP60 and HSP10 during carcinogenesis of the prostate as well as of other organs.